E-viri
Recenzirano
Odprti dostop
-
Satoh, Taroh; Kang, Yoon-Koo; Chao, Yee; Ryu, Min-Hee; Kato, Ken; Cheol Chung, Hyun; Chen, Jen-Shi; Muro, Kei; Ki Kang, Won; Yeh, Kun-Huei; Yoshikawa, Takaki; Oh, Sang Cheul; Bai, Li-Yuan; Tamura, Takao; Lee, Keun-Wook; Hamamoto, Yasuo; Kim, Jong Gwang; Chin, Keisho; Oh, Do-Youn; Minashi, Keiko; Cho, Jae Yong; Tsuda, Masahiro; Tanimoto, Mitsunobu; Chen, Li-Tzong; Boku, Narikazu
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 01/2020, Letnik: 23, Številka: 1Journal Article
Background Data on immune checkpoint inhibitor efficacy in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced gastric/gastroesophageal junction (G/GEJ) cancer are lacking. Because HER2 status was not captured in the ATTRACTION-2 trial, we used patients with prior trastuzumab use (Tmab+) as surrogate for HER2 expression status to evaluate the efficacy and safety of nivolumab as third- or later-line therapy in these patients. Methods In ATTRACTION-2, a randomized, double-blind, placebo-controlled, phase 3 multicenter trial, patients were randomized (2:1) to receive nivolumab (3 mg/kg) or placebo every 2 weeks until disease progression or toxicity requiring study discontinuation. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety were assessed. Results Of 493 enrolled patients, 81 (nivolumab, n = 59; placebo, n = 22) were Tmab+ and 412 (nivolumab, n = 271; placebo, n = 141) were Tmab−. In both groups, patients receiving nivolumab showed a longer median OS vs placebo (Tmab+, 8.3 95% confidence interval, 5.3–12.9 vs 3.1 1.9–5.3 months, hazard ratio, 0.38 0.22–0.66; P = 0.0006; Tmab−, 4.8 4.1–6.0 vs 4.2 3.6–4.9 months, 0.71 0.57–0.88; P = 0.0022). PFS was longer in both groups receiving nivolumab vs placebo (Tmab+, 1.6 1.5–4.0 vs 1.5 1.3–2.9 months, 0.49 0.29–0.85; P = 0.0111; Tmab−, 1.6 1.5–2.4 vs 1.5 1.5–1.5 months, 0.64 0.51–0.80; P = 0.0001). Conclusions Nivolumab was efficacious and safe as third- or later-line therapy regardless of prior trastuzumab use in patients with advanced G/GEJ cancer.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.